More Sessions Announced!

Explore the key topics & themes shaping this year's summit

STAT Summit News

Announcing Two New Sessions: Summit Therapeutics and Health Care's Colossus

Dear STAT reader –

I want to highlight two new sessions added to our STAT Summit agenda, taking place in Boston on October 16 and 17. These sessions showcase the two most compelling reasons to join us in person: our independent investigative journalism and access to top newsmakers.

"Health Care's Colossus," STAT's series on UnitedHealth Group, has been one of our most well-read and well-received series this year, focusing on how America's largest health insurance company has used its empire of physician practices to boost its profits and extend its influence. These stories grew out of earlier work by Bob Herman and Casey Ross, for which they were named Pulitzer finalists, that examined how UnitedHealth may have used AI algorithms to deny patients care.

On stage, Tara Bannow, a hospitals and insurance reporter at STAT, will interview some of the key sources from this series about the effect they see UnitedHealth having on medical care. It's a chance to get a first-hand look at one of the biggest stories in medicine. The session will occur on Oct. 16.

I'm also thrilled to announce that Bob Duggan and Maky Zanganeh, the CEOs of Summit Therapeutics, will join us on Oct. 17 for an in-person interview. Summit recently announced that Ivonescimab, the experimental cancer drug it is developing with Chinese partner Akeso, outperformed Keytruda, the best-selling drug in the world, in a study in lung cancer.

STAT's Adam Feuerstein has said this "may be the story of the year." Investors have Summit the stock up 1,100% in 2024. You can read more about Duggan and Zanganeh here – and you'll be able to see me interview them live on stage.

Take a look at the full agenda now. I'd love to see you there.